Redefining Immunity: The Rise of AASI

📣 New Publication Alert!

We’re proud to share the release of our latest peer-reviewed review article in the American Journal of Biomedical Science & Research:

Autologous Antigen-Specific Immunotherapy (AASI): Precision Immune Re-Education in Autoimmunity and Beyond
By Prof. Dr. Mike K.S. Chan, Prof. Dr. Michelle B.F. Wong, Krista Casazza, Prof. Dr. Dmytro Klokol, Dr. Waldemar Lernhardt, Ian Jenkins and Prof. Jonathan R.T. Lakey
📅 Published: July 29, 2025

Autologous Antigen-Specific Immunotherapy (AASI) is redefining how we treat autoimmune and immune-mediated diseases, from Type 1 diabetes and multiple sclerosis to allergies, organ transplantation, and even cancer.

In this comprehensive new article, discover how AASI leverages a patient’s own immune cells to restore immune tolerance with precision, safety, and potential applications across diverse clinical fields.

🔬 Key Highlights:

✔️ Explains how AASI targets disease-causing antigens while preserving normal immunity
✔️ Showcases cutting-edge AASI platforms: tolerogenic dendritic cells (tolDCs), nanoparticles, peptide conjugates, and CAR-Tregs
✔️ Explores clinical potential for autoimmune diseases (T1D, MS, SLE, RA), allergies, transplant rejection, and cancer
✔️ Highlights challenges and future directions in biomarker profiling, AI-guided antigen selection, and personalized delivery systems
✔️ Emphasizes safety and selectivity as the next frontier in immune tolerance therapy

This review calls for a shift from immunosuppression to immune education toward a future of targeted, lasting, and safer interventions.

🧬 AASI isn’t just a treatment. It’s a paradigm shift in immunotherapy.

WATCH THE VIDEO: https://youtube.com/shorts/utiLqsB4Kx8

🌐 Read more here:

📖 Learn more about the publication here:
🔗https://european-wellness.eu/publications/autologous-antigen-specific-immunotherapy/

📖 Full Access:
🔗 https://biomedgrid.com/pdf/AJBSR.MS.ID.003623.pdf

📖 More publications here:
🔗 https://european-wellness.eu/publications/